{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":26,"n_cols":5,"rows_kept":26,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[14,2,14,3],[15,2,15,3],[17,2,17,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910743341503321"]
[null,null,"Titolo",null,"Advanced drug delivery strategies for targeting chronic inflammatory lung diseases / / Dinesh Kumar Chellappan, Kavita Pabreja and Md. Faiyazuddin, editors"]
[null,null,"Pubbl/distr/stampa",null,"Singapore : , : Springer, , [2022]"]
[{"$nulls":4},"©2022"]
[null,null,"ISBN",null,"981-16-4392-X"]
[{"$nulls":4},"981-16-4391-1"]
[null,null,"Descrizione fisica",null,"1 online resource (652 pages)"]
[null,null,"Disciplina",null,"615.6"]
[null,null,"Soggetti",null,"Drug delivery systems"]
[{"$nulls":4},"Lungs - Diseases - Treatment"]
[{"$nulls":4},"Nanoparticles"]
[{"$nulls":4},"Malalties del pulmó"]
[{"$nulls":4},"Dispositius d'administració de medicaments"]
[{"$nulls":4},"Llibres electrònics"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Intro -- Contents -- About the Editors -- 1: An Introduction to Respiratory Diseases and an Emerging Need for Efficient Drug Delivery Systems -- 1.1 Current Treatments for Respiratory Diseases -- 1.1.1 Bronchodilators -- 1.1.2 Corticosteroids -- 1.1.3 Antibiotics -- 1.1.4 Bronchodilators -- 1.2 Challenges to the Current Treatment of Drugs -- 1.2.1 Asthma -- 1.2.2 Chronic Obstructive Pulmonary Disease (COPD) -- 1.2.3 Interstitial Lung Diseases (ILDs) -- 1.2.4 Cystic Fibrosis (CF) -- 1.2.5 Lung Cancer -- 1.2.6 Respiratory Infections -- 1.3 Pulmonary Drug Delivery Systems -- 1.4 Limitations of the Drug Delivery Systems -- 1.5 The Need of Novel Drug Delivery Systems -- 1.6 Conclusion -- References -- 2: Inflammatory Respiratory Diseases: Correlation Between Lung Cancer and COVID-19 -- 2.1 Epidemiology -- 2.1.1 Introduction -- 2.1.2 Incidence -- 2.1.3 Mortality -- 2.1.4 Survival -- 2.2 Lung Cancer Among Never Smokers -- 2.2.1 Risk Factors -- 2.2.1.1 Passive Smoking -- 2.2.2 Cooking Fumes -- 2.2.3 Inherited Genetic Susceptibility -- 2.2.4 Preexisting Lung-Related Disease -- 2.2.5 Clinical Profile of Lung Cancer Among Never Smokers -- 2.3 Lung Cancer Screening, Diagnosis, and Treatment -- 2.3.1 "]
[{"$nulls":4},"Screening -- 2.3.2 Diagnosis -- 2.3.2.1 PET with Computed Tomography (PET-CT) -- 2.3.2.2 Magnetic Resonance Imaging (MRI) -- 2.3.3 Bronchoscopy -- 2.3.3.1 Fiberoptic Bronchoscopy -- 2.3.4 Endobronchial Ultrasound (EBUS) and Endoscopic (Esophageal) Ultrasound (EUS) -- 2.3.5 Transthoracic Needle Biopsy -- 2.3.5.1 Treatment -- 2.3.5.2 Surgery -- 2.3.5.3 Chemotherapy -- 2.3.5.4 Targeted Therapy -- 2.3.5.5 Immunotherapy -- 2.3.5.6 Radiation -- 2.4 Lung Cancer and COVID-19 -- 2.4.1 Introduction -- 2.4.2 Lung Cancer to a COVID-19 Risk Factor -- 2.4.3 Why Are Lung Cancer Patients Prone to Getting Infected with COVID-19?."]
[{"$nulls":4},"2.4.4 Lung Cancer Management During Diagnosis and Staging -- 2.5 Conclusion -- References -- 3: Advancements in Translational Respiratory Research Using Nanotechnology -- 3.1 Introduction -- 3.2 Advancements in Translational Respiratory Research (TRR) -- 3.3 Overview of Nanomedicine and Nanotechnology -- 3.3.1 Types of Nanoparticles -- 3.3.1.1 Carbon-Based Nanoparticles -- 3.3.1.2 Metal Nanoparticles -- 3.3.1.3 Ceramic Nanoparticles -- 3.3.1.4 Semiconductor Nanoparticles -- 3.3.1.5 Polymeric Nanoparticles -- 3.3.1.6 Lipid-Based Nanoparticles -- 3.3.2 Synthesis of Nanoparticles -- 3.3.2.1 Bottom-Up Method -- 3.3.2.2 Top-Down Method -- 3.3.3 Characterization of Nanoparticles -- 3.4 Inhalation Drug Delivery -- 3.4.1 Barriers to the Inhalation Drug Delivery System -- 3.4.2 Nanoparticles in Inhalation Drug Delivery -- 3.4.3 Clinical Studies on Inhalation Drug Delivery -- 3.5 Oligonucleotide Therapy -- 3.5.1 Antisense Oligonucleotides (ASOs) -- 3.5.2 Short Interfering RNA (siRNA) -- 3.5.3 MicroRNA (miRNA) -- 3.5.4 Aptamers -- 3.5.5 Cytosine-Guanine Dinucleotide (CpG) Oligonucleotides -- 3.5.6 Delivery of Oligonucleotide Therapy -- 3.5.7 Clinical Studies on Oligonucleotide Therapy -- 3.6 Photodynamic Therapy (PDT) -- 3.6.1 Nanoparticles in PDT -- 3.6.2 Clinical Studies on Photodynamic Therapy -- 3.7 Future Prospects -- 3.8 Conclusion -- References -- 4: Chemical Moieties as Advanced Therapeutics for Targeting Respiratory Disorders -- 4.1 Introduction -- 4.2 Indole-Based Chemical Compounds for Managing Respiratory Disorders -- 4.3 Azole-Based Chemical Compounds for Managing Respiratory Disorders -- 4.4 Chromone-Based Conjugates for Capping Respiratory Disorders -- 4.5 Flavonoid-Based Conjugates for Capping Respiratory Disorders -- 4.6 Terpenoid-Based Conjugates for Capping Respiratory Disorders -- 4.7 Alkaloids for Capping Respiratory Disorders."]
[{"$nulls":4},"4.8 Essential Patented Molecules for Ameliorating Respiratory Disorders -- 4.9 Conclusion -- References -- 5: Phytochemicals and their Nanoformulations Targeted for Pulmonary Diseases -- 5.1 Introduction -- 5.2 Phytochemical Nanoformulations Targeted for Lung Diseases -- 5.2.1 Curcumin -- 5.2.2 Resveratrol -- 5.2.3 Naringenin -- 5.2.4 (-)-Epigallocatechin-3-O-Gallate (EGCG) -- 5.2.5 Berberine -- 5.2.6 Celastrol -- 5.3 Conclusion and Future Prospects -- References -- 6: Nanocarriers: An Advanced and Highly Effective Approach for Targeting Chronic Lung Diseases -- 6.1 Introduction -- 6.2 Advanced Drug Delivery and Its Implication in Chronic Inflammatory Lung Disease -- 6.3 Nanocarriers Investigated in Advanced Drug Delivery for Targeting Chronic Lung Disease -- 6.3.1 Liposomes -- 6.3.2 Dendrimers -- 6.3.3 Polymeric Nanoparticles -- 6.3.4 Micelles -- 6.3.5 Carbon Nanotubes -- 6.3.6 Quantum Dots -- 6.3.7 Exosomes -- 6.3.8 Solid Lipid Nanoparticles -- 6.4 Synthetic Approaches of Polymeric Nanoparticle Formulation -- 6.5 Drugs Delivered Through Advanced Drug Delivery Strategies: Nanocarriers -- 6.6 Conclusions and Future Prospects -- References -- 7: Vesicular Drug Delivery Systems in Respiratory Diseases -- 7.1 Introduction -- 7.2 Global Prevalence of Major "]
[{"$nulls":4},"Respiratory Diseases -- 7.3 Conventional Therapies Used for Respiratory Diseases -- 7.4 Antibiotics -- 7.5 Anti-Inflammatory Drugs -- 7.6 Bronchodilators -- 7.7 Gene Therapy -- 7.8 Vesicular Drug Delivery System (VDDS) for Respiratory Disease Treatment -- 7.8.1 Liposomes -- 7.8.2 Virosomes -- 7.8.3 Niosomes -- 7.8.4 Proniosomes -- 7.8.5 Archaesome -- 7.8.6 Ethosomes -- 7.8.7 Others -- 7.9 Conclusion and Future Perspective -- References -- 8: Nanoparticles in Chronic Respiratory Diseases -- 8.1 Introduction -- 8.1.1 Chronic Respiratory Disease -- 8.1.2 Nanoparticle Size for Alveoli Delivery."]
[{"$nulls":4},"8.2 Lipid-Based Nanoparticle -- 8.2.1 Liposomes -- 8.2.2 Lipid Polymer Hybrid -- 8.2.3 Solid Lipid Nanoparticle -- 8.2.4 Nanostructured Lipid Carrier -- 8.3 Polysaccharides-Based Nanoparticles -- 8.4 Polymer-Based Nanoparticles (PNS) -- 8.5 Dendrimers -- 8.6 Inorganic Nanoparticles -- 8.6.1 Development of Inorganic Nanoparticles -- 8.6.1.1 Precipitation of Salts in Aqueous Media -- 8.6.1.2 Hydrothermal Method -- 8.6.1.3 Microemulsion Method -- 8.6.1.4 Polyol Process -- 8.6.1.5 Thermal Decomposition -- 8.6.2 Inorganic-Based Nanomaterials -- 8.6.2.1 Carbon Nanotubes -- 8.6.2.2 Gold Nanoparticles -- 8.6.2.3 Silver Nanoparticles -- 8.6.2.4 Platinum Nanoparticles -- 8.6.2.5 Magnetic Nanoparticles (MNPs) -- 8.6.2.6 Iron-Oxide Nanoparticles -- 8.6.2.7 Zinc Oxide Nanoparticles -- 8.6.2.8 Copper Oxide Nanoparticle -- 8.6.3 Inorganic Nanoparticles in Chronic Respiratory Diseases -- 8.7 Advanced Nanomedicine for Chronic Respiratory Diseases -- 8.7.1 Clinical Studies for Targeted Drug Delivery -- 8.7.1.1 Cystic Fibrosis -- 8.7.1.2 Lung Cancer -- 8.7.1.3 Asthma -- 8.7.2 Theranostics (Diagnosis and Imaging Based on Nanotechnology) -- 8.8 Conclusion -- References -- 9: Applications of Nanotechnology in Pulmonary Disease Diagnosis -- 9.1 Introduction -- 9.2 Promising Nanotechnological Interventions for Pulmonary Disease Diagnosis -- 9.2.1 Nanoparticle-Based Nano-Platforms for Diagnostic Imaging in Pulmonary Diseases -- 9.2.1.1 Gold NPs -- 9.2.1.2 Iron Oxide NPs -- 9.2.1.3 Polymeric NPs -- 9.2.1.4 Silica-Based NPs -- 9.2.1.5 Manganese Oxide NPs -- 9.2.1.6 Gadolinium-Based NPs -- 9.2.1.7 Miscellaneous -- 9.3 Nano-Biosensors for Pulmonary Disease Diagnosis -- 9.3.1 Nano-Biosensors for the Diagnosis of Tuberculosis -- 9.3.2 Nano-Biosensors for the Diagnosis of Lung Cancer -- 9.3.3 Nano-Biosensors for Diagnosis of Pulmonary Arterial Hypertension."]
[{"$nulls":4},"9.4 Quantum Dots/Nanocrystal Fluorophores-Based Nano-Platforms for Pulmonary Disease Diagnosis -- 9.5 Conclusion and Future Perspectives -- References -- 10: Nanotechnology in Pulmonary Disease Diagnosis -- 10.1 Introduction -- 10.2 Nanotechnology as a Diagnosis Tool -- 10.2.1 Ex Vivo Diagnosis -- 10.2.2 In Vivo Diagnosis -- 10.3 Nanotechnology in the Diagnosis of Pulmonary Diseases -- 10.4 Summary and Conclusion -- References -- 11: Recent Trends in Nanomedicine for Diagnosis and Treatment of Pulmonary Diseases -- 11.1 Introduction -- 11.1.1 Classification of Respiratory Diseases -- 11.1.2 Nanomedicine -- 11.1.3 Application of Nanomedicine in Respiratory Diseases -- 11.1.4 Diagnosis and Treatment -- 11.1.5 Obstructive Pulmonary Diseases -- 11.1.6 Pulmonary Tuberculosis -- 11.1.7 Lung Cancer -- 11.2 Targeted Drug Delivery in Pulmonary Diseases -- 11.3 Types of Nanoparticle-Based Treatment for Pulmonary Diseases -- 11.3.1 Solid Lipid Nanoparticles (SLN) -- 11.3.2 Polymeric Nanoparticles -- 11.4 Conclusion and Future Perspectives -- References -- 12: Strategies for Enhanced Drug Targeting to Inflamed Lungs: Novel Perspectives -- 12.1 Introduction -- 12.2 Anatomy and Physiology of Human Lungs -- 12.2.1 Bronchial Tree -- 12.2.1.1 Tracheal Airways -- 12.2.1.2 Bronchi and Bronchioles -- 12.2.2 Alveoli "]
[{"$nulls":4},"-- 12.2.3 Pulmonary Blood Circulation -- 12.2.4 Physiology of Lungs -- 12.2.4.1 Pulmonary Mechanics -- 12.2.4.2 Inspiration -- 12.2.4.3 Expiration -- 12.2.4.4 Gas Exchange -- 12.3 Chronic Inflammatory Lung Diseases -- 12.3.1 Asthma -- 12.3.1.1 Pathogenesis of Asthma -- 12.3.2 Chronic Obstructive Pulmonary Disease (COPD) and Emphysema -- 12.3.2.1 Pathogenesis of COPD (Chronic Bronchitis and Emphysema) -- 12.3.3 Idiopathic Pulmonary Fibrosis (IPF) -- 12.3.3.1 Pathogenesis of IPF -- 12.4 Nanodiagnosis of CILD."]
[{"$nulls":4},"12.5 Strategies for Enhanced Drug Targeting to Inflamed Lungs."]